Streetbeat News

Regulatory

AMTX

Aemetis, Inc. has received approval from the US Citizenship and Immigration Services for $200 million of investments under the EB-5 Program. This program allows foreign investors to invest in US projects that create jobs in exchange for a chance to earn a green card. The approval marks a significant milestone for Aemetis, potentially boosting its project funding capabilities and accelerating its growth initiatives.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 12:06 pm

VRTX

Vertex Pharmaceuticals has received FDA clearance for its Investigational New Drug application for VX-407, aimed at treating Autosomal Dominant Polycystic Kidney Disease. The company plans to begin a Phase 1 clinical trial with healthy volunteers within the month.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 12:03 pm

LSTA

Lisata Therapeutics has received a Rare Pediatric Disease Designation from the US FDA for LSTA1, aimed at treating Osteosarcoma. This designation could potentially expedite the development and review process for LSTA1, enhancing Lisata Therapeutics' position in the market for rare pediatric diseases.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 12:02 pm

FIVE

QQQ

SCS

SPY

U.S. stocks are poised for further gains, buoyed by optimism following the Fed's dovish stance and anticipation of rate cuts. The rally is broadening beyond tech stocks, with small-caps and various sectors showing strength. Key economic data and earnings reports are in focus. Futures indicate a positive opening, with SPY and QQQ ETFs up in premarket trading. Micron Technology surged on earnings, while Steelcase and Five Below declined. Other notable earnings include Accenture, Darden Restaurants, Winnebago, Shoe Carnival, FedEx, Lululemon, NIKE, and Worthington Steel.

Portfolio Pulse from Shanthi Rexaline

March 21, 2024 | 11:35 am

AZN

GSK

TEVA

GSK Plc announced a cap on out-of-pocket costs for its asthma and COPD medicines at $35 per month, starting January 1, 2025. This follows a similar move by AstraZeneca Plc, and both are in response to criticism from the HELP Committee over high inhaler prices in the U.S. compared to other countries. Teva Pharmaceutical Industries Limited was also mentioned as one of the companies criticized for high inhaler prices. GSK shares saw a slight increase in premarket trading.

Portfolio Pulse from Vandana Singh

March 21, 2024 | 11:17 am

IFRX

InflaRx plans to target chronic spontaneous urticaria and hidradenitis suppurativa with its INF904 drug, initiating a Phase 2a PK dose-ranging study by the end of 2024. Results from the study are expected to be available in 2025.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 11:15 am

FTEC

IXN

MSFT

Microsoft Corp (NASDAQ:MSFT) is facing increased scrutiny from U.S. Senators, including Marco Rubio and Mark Warner, over Bing's censorship practices in China, as revealed by a Bloomberg Businessweek investigation. The criticism centers on Bing's compliance with Chinese government censorship demands, filtering content related to human rights, democracy, and more. Human Rights Watch has called for Microsoft to disclose its content removal practices. Additionally, Microsoft executives have been involved in discussions about AI and trade with China, amidst warnings from U.S. lawmakers about technological collaborations. Microsoft stock has seen a 55% increase over the last 12 months, with exposure available through IShares Global Tech ETF (NYSE:IXN) and Fidelity MSCI Information Technology Index ETF (NYSE:FTEC).

Portfolio Pulse from Anusuya Lahiri

March 21, 2024 | 11:12 am

TELA

TELA Bio announced the U.S. commercial launch of LIQUIFIX, the only FDA-approved liquid adhesive for internal use in hernia surgery. This product is expected to revolutionize the way hernia surgeries are performed by providing a new, innovative solution for surgeons.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 11:12 am

GLD

SPY

USO

UUP

Global markets saw gains with the S&P 500, Dow Jones, and Nasdaq all closing higher after the Federal Reserve announced it would keep borrowing costs stable and hinted at possible rate cuts. Gold surged to a record high, crossing $2,200. Asian and European markets also experienced gains, with notable increases in Japan's Nikkei 225 and Australia's S&P/ASX 200. U.S. crude oil stocks fell unexpectedly, and the U.S. Dollar Index dropped.

Portfolio Pulse from Akanksha Bakshi

March 21, 2024 | 10:54 am

LEG

WEN

Wall Street's most accurate analysts have provided their views on three consumer discretionary stocks with high dividend yields: Leggett & Platt, Ford Motor Company, and The Wendy's Company. These stocks offer dividend yields ranging from 4.65% to 9.75%. The analysis includes recent ratings, price target adjustments, and significant news impacting each company, such as financial results and regulatory probes.

Portfolio Pulse from Avi Kapoor

March 21, 2024 | 10:52 am